Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

Core Insights - Cognition Therapeutics, Inc. has successfully completed enrollment in its expanded access program for zervimesine, with participants receiving 100 mg daily for up to one year [1][2] - The company has scheduled a Type C meeting with the U.S. FDA for the second half of January to discuss the proposed design of a Phase 3 program for zervimesine in dementia with Lewy bodies (DLB) [2][3] Expanded Access Program - The COG1202 expanded access program is open-label and includes eligible participants from the Phase 2 SHIMMER study and additional patients diagnosed with mild-to-moderate DLB [3] - Dr. James E. Galvin is the lead investigator for this multi-center program [3] Zervimesine (CT1812) - Zervimesine is an investigational oral medication aimed at treating CNS diseases, specifically Alzheimer's disease and DLB, by interrupting the toxic effects of Aβ and ɑ-synuclein [4] - The drug has shown a good safety profile in clinical studies to date [4][5] Company Overview - Cognition Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for age-related degenerative disorders of the central nervous system [6] - The company has completed Phase 2 studies for zervimesine in DLB and mild-to-moderate Alzheimer's disease, with ongoing studies in early Alzheimer's disease [6]